Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIa Clinical Study to Evaluate Safety and to Explore Efficacy of N-Rephasin SAL200, in Patients With Persistent Staphylococcus Aureus Bacteremia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Tonabacase (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions
- Sponsors iNtRON Biotechnology
- 22 Jul 2021 Status changed from completed to discontinued.
- 28 Jan 2021 Status changed from recruiting to completed.
- 06 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Apr 2020.